BeiGene Ltd logo

BeiGene Ltd - ADR

MEX:BGNE (Cayman Islands)   ADR
MXN 2858.16 (0%) Sep 27
At Loss
P/B:
6.87
Market Cap:
MXN 303.19B ($ 15.40B)
Enterprise V:
MXN 273.60B ($ 13.89B)
Volume:
-
Avg Vol (2M):
-
Trade In:

Business Description

Description
BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.
Name Current Vs Industry Vs History
Cash-To-Debt 2.38
Equity-to-Asset 0.59
Debt-to-Equity 0.32
Debt-to-EBITDA -1.38
Interest Coverage N/A
N/A
N/A
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 4.86
Distress
Grey
Safe
Beneish M-Score -1.97
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
12-1 Month Momentum % -25.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 1.98
Quick Ratio 1.75
Cash Ratio 1.34
Days Inventory 305.21
Days Sales Outstanding 45.53
Days Payable 253.2

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -4.4
Shareholder Yield % -1.16

Financials (Next Earnings Date:2024-11-08 Est.)

MEX:BGNE's 30-Y Financials
Income Statement Breakdown FY
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

BeiGene Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil MXN) 53,939.549
EPS (TTM) (MXN) -89.306
Beta 0.37
Volatility % 25.95
14-Day RSI 0
14-Day ATR (MXN) 0.000115
20-Day SMA (MXN) 2858.16
12-1 Month Momentum % -25.95
52-Week Range (MXN) 2858.16 - 3860
Shares Outstanding (Mil) 106.08

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

BeiGene Ltd Filings

Filing Date Document Date Form
No Filing Data

BeiGene Ltd Stock Events

Financials Calendars
Event Date Price(MXN)
No Event Data

BeiGene Ltd Frequently Asked Questions

What is BeiGene Ltd(MEX:BGNE)'s stock price today?
The current price of MEX:BGNE is MXN2858.16. The 52 week high of MEX:BGNE is MXN3860.00 and 52 week low is MXN2858.16.
When is next earnings date of BeiGene Ltd(MEX:BGNE)?
The next earnings date of BeiGene Ltd(MEX:BGNE) is 2024-11-08 Est..
Does BeiGene Ltd(MEX:BGNE) pay dividends? If so, how much?
BeiGene Ltd(MEX:BGNE) does not pay dividend.

Press Release

Subject Date
No Press Release